..
..
Encouraging news with UPDATED DATA! Moderna's Omicron bivalent booster vaccine candidate, mRNA-1273.214, has demonstrated superior neutralizing antibody responses against ALL variants of concern INCLUDING Omicron subvariants BA.4, BA.5, AND BA.2.75! Let’s talk about that! 🧵
— Chise 🔜 TFF GOH (@sailorrooscout) October 19, 2022
If you guys remember, back in June I wrote on Moderna's bivalent booster vaccine candidate, mRNA-1273.214, which has equal mRNA amounts of ancestral SARS-CoV-2 and Omicron (BA.1) variant spike proteins. This data has since been PEER-REVIEWED in NEJM.
— Chise 🔜 TFF GOH (@sailorrooscout) October 19, 2022
•https://t.co/iQCiaaJuFO
(mRNA-1273) with their Omicron-specific booster (mRNA-1273.529). Just so we are all on the same page: THIS IS THE BA.1 BIVALENT BOOSTER. I’ll explain more in regards to mRNA-1273.222 (BA.4/BA.5) below.
— Chise 🔜 TFF GOH (@sailorrooscout) October 19, 2022
•https://t.co/FWiiyNweT6
•https://t.co/zxRmja2n2W
SUGGESTING THAT the bivalent booster elicits broad cross-neutralization against Omicron variants. mRNA-1273.214 has now demonstrated significantly higher antibody titers against ALL tested variants, including Omicron subvariants BA.1, BA2.75, and BA.4/.5, ancestral virus,
— Chise 🔜 TFF GOH (@sailorrooscout) October 19, 2022
compared to the original vaccine (mRNA-1273) REGARDLESS of prior infection status or age (adults over 18, greater or less than 65 years old). Among participants WITHOUT prior infection, mRNA-1273.214 resulted in significantly higher neutralizing titers against BA.4/5 compared to
— Chise 🔜 TFF GOH (@sailorrooscout) October 19, 2022
the world. Moderna expects interim safety and immunogenicity results of its Omicron BA.4/BA.5-targeting bivalent vaccine, mRNA-1273.222, to become available later this year. While we wait for the data manuscript see:
— Chise 🔜 TFF GOH (@sailorrooscout) October 19, 2022
•https://t.co/Ivjr5seSRn
•https://t.co/GDi207duUZ
..
weehingthong 